Targeting HER1/EGFR in cancer therapy: experience with erlotinib
G Giaccone - Future Oncology, 2005 - Taylor & Francis
Research into the role of the human epidermal receptor growth factor receptor 1/epidermal
growth factor receptor (HER1/EGFR) in tumorigenesis has generated a new class of …
growth factor receptor (HER1/EGFR) in tumorigenesis has generated a new class of …
Preclinical studies with erlotinib (Tarceva)
RW Akita, MX Sliwkowski - Seminars in oncology, 2003 - Elsevier
Erlotinib HCl (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …
Erlotinib (Tarceva®): a promising drug targeting epidermal growth factor receptor tyrosine kinase
AM Bulgaru, S Mani, S Goel… - Expert review of …, 2003 - Taylor & Francis
Overexpression of the epidermal growth factor receptor (EGFR) is correlated with a poor
prognosis in several human malignancies. In addition, cancers overexpressing EGFR …
prognosis in several human malignancies. In addition, cancers overexpressing EGFR …
Erlotinib (Tarceva): an update on the clinical trial program
RS Herbst - Seminars in oncology, 2003 - Elsevier
Erlotinib HCI (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
quinazoline-based agent that competes with adenosine triphosphate for binding with the …
quinazoline-based agent that competes with adenosine triphosphate for binding with the …
Erlotinib: preclinical investigations.
M Hidalgo - Oncology (Williston Park, NY), 2003 - europepmc.org
Erlotinib (Tarceva) is an orally available selective small-molecule inhibitor of HER1/EGFR
tyrosine kinase with a 50% inhibitory concentration of 2 nM for purified tyrosine kinase. This …
tyrosine kinase with a 50% inhibitory concentration of 2 nM for purified tyrosine kinase. This …
Erlotinib in cancer treatment
MA Bareschino, C Schettino, T Troiani, E Martinelli… - Annals of oncology, 2007 - Elsevier
The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase (TK)
receptor that is frequently expressed in many epithelial tumors. The signaling pathways of …
receptor that is frequently expressed in many epithelial tumors. The signaling pathways of …
Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.
A Sandler - Oncology (Williston Park, NY), 2003 - europepmc.org
In phase I trials in healthy volunteers and patients with refractory cancers, erlotinib (Tarceva)
was well tolerated and showed activity against non-small-cell lung cancer and other tumors …
was well tolerated and showed activity against non-small-cell lung cancer and other tumors …
Challenges and opportunities for Erlotinib (Tarceva): what does the future hold?
GN Hortobagyi, G Sauter - Seminars in oncology, 2003 - Elsevier
The development of targeted agents has brought new opportunities and extraordinary
therapeutic challenges to cancer therapy. Several agents that inhibit epidermal growth factor …
therapeutic challenges to cancer therapy. Several agents that inhibit epidermal growth factor …
Recent developments related to the EGFR as a target for cancer chemotherapy
G Speake, B Holloway, G Costello - Current opinion in pharmacology, 2005 - Elsevier
Inhibition of the epidermal growth factor receptor as a target for cancer chemotherapy has
proven to be an effective treatment in both preclinical and clinical settings. Recent work has …
proven to be an effective treatment in both preclinical and clinical settings. Recent work has …